This concise guideline summarises the key recommendations from the recent National Institute for Health and Care Excellence (NICE) clinical guideline on the assessment and management of psoriasis (CG153) that are relevant to the nondermatologist. The aim is to highlight important considerations for assessment and referral of people with psoriasis, including identifi cation of relevant comorbid conditions. Psoriasis is a common infl ammatory skin condition and, especially when severe, can be associated with increased risk of cardiovascular disease, diabetes and depression. Functional, psychological and social morbidity can also be encountered, and the extent of the disability is frequently underestimated. Importantly, highly effective treatments are available. Appropriate assessment and referral of people with psoriasis therefore has the potential to improve outcomes by correctly identifying the appropriate treatment pathway. Assessment should involve not only disease severity but also the impact on patient well-being and whether the patient has any comorbid conditions, such as psoriatic arthritis, which requires rapid referral to a rheumatologist.
Introduction
Psoriasis is an infl ammatory skin disease that typically follows a relapsing and remitting course. The prevalence of psoriasis is estimated to be about 1.3-2.2% in the UK 1 and it is associated with joint disease -psoriatic arthritis -in a signifi cant proportion of patients (13.8% in one study). 2 The different phenotypes of psoriasis include:
> plaque psoriasis (about 90% of cases): well-delineated red, scaly plaques > guttate psoriasis: an acute eruption of small papules, which is often preceded by streptococcal infection > pustular psoriasis: localised or generalised.
Distinctive nail changes occur in about 50% of all those affected and are more common in people with associated joint disease. People with psoriasis, particularly those with severe disease, are also at increased risk of a number of comorbidities, including depression, alcohol-related problems, cardiovascular disease, metabolic syndrome and non-melanoma skin cancer. [3] [4] [5] [6] [7] Many people with psoriasis experience profound functional, psychological and social morbidity, with consequently reduced levels of employment and income. Factors that contribute to this include:
> symptoms related to the skin (for example, chronic itching, bleeding, scaling and nail involvement) > problems related to treatments, many of which can be messy and time consuming > psoriatic arthritis > the impact of living with a highly visible and stigmatising skin disease.
Doctors, including dermatologists, often fail to appreciate the extent of disability, and many people with psoriasis are dissatisfi ed with their treatment, although highly effective and cost-effective treatments are available. 8 The National Institute for Health and Care Excellence (NICE) clinical guideline on psoriasis, which was published in 2012, 9 provides comprehensive recommendations on the assessment and management of all types of psoriasis, with information on the spectrum of available active interventions -from simple creams and ointments through to phototherapy and standard systemic and biologic treatments.
Although most people with psoriasis are managed in primary care, healthcare professionals working in acute and/or nondermatological specialist settings are also highly likely to come into contact with affected patients. Psoriasis is common and will be a coincidental fi nding in many patients; specialist input may be requested in relation to comorbid conditions or complications from treatments for psoriasis -for example, patients may develop tumour necrosis factor (TNF) antagonistrelated reactivation of tuberculosis or methotrexate-related hepatotoxicity and patients with very severe and unstable disease may become systemically unwell and require inpatient or intensive care management. Improved awareness of the condition among non-specialist clinicians thus will benefi t people with psoriasis.
Scope and purpose
This concise guideline summarises some of the key recommendations detailed in the full NICE guideline. 9 It is intended for use by all healthcare professionals who encounter patients with psoriasis and focuses on assessment and referral as relevant to the non-dermatologist, including identifi cation of relevant comorbid conditions. A summary of the overall care pathway is also included to provide some context. Please refer to the full NICE guideline 9 for recommendations on the use of specifi c treatment options.
The recommendations
Holistic assessment of patients with psoriasis presenting to any healthcare professional should encompass the psoriasis itself and the impact the disease has on the individual's wellbeing. Both dimensions are important to ensure that patients are directed towards appropriate services and treatments to meet their individual requirements and minimise morbidity. Currently, there are no biomarkers for disease activity in psoriasis, so 'measurement' is based on clinical evaluation of the skin. In addition, the impact of psoriasis on an affected person's well-being can be underestimated by clinicians managing skin disease, even in specialist settings, which makes formal assessment important. Early assessment for psoriatic arthritis is also important to ensure timely access to rheumatology services and to minimise associated progressive joint damage and loss of function. 10 Similarly, identifi cation of those at risk of cardiovascular disease is key to early management of modifi able risk factors.
Formal assessment will determine the optimal treatment approach. To date, no treatment has been shown to alter the overall prognosis, so choice of intervention is strongly infl uenced by how much the psoriasis is bothering the patient, the extent and site of disease, and the presence of arthritis. Topical therapy (fi rst line) is the mainstay of treatment for mild-to-moderate psoriasis. Second-line therapy includes phototherapy with broad-or narrow-band ultraviolet (UV) B light or psoralen plus UVA light (PUVA) and systemic nonbiologic agents such as ciclosporin, methotrexate and acitretin. Third-line therapy comprises biologic therapies such as the TNF antagonists (eg adalimumab, etanercept and infl iximab) and ustekinumab, which have revolutionised the treatment of severe disease, with a consequent 90% reduction in demand for inpatient management (Fig 1) .
Based on these principles and the available evidence, CG153 made 109 recommendations. Table 1 highlights those of particular relevance to non-specialist clinicians, especially those that, when implemented, might generate referrals outside of the dermatology setting.
Offer narrowband UVB phototherapy to paƟents with plaque or guƩate paƩern psoriasis that cannot be treated with topical therapy alone.
Offer systemic non-biological therapy to people with any type of psoriasis if:
> it cannot be controlled with topical therapy > it has a significant impact on physical, psychological or social well-being > one or more of the following apply: -extensive disease -localised disease associated with significant funcƟonal impairment or distress -phototherapy has been ineffecƟve, cannot be used or has resulted in rapid relapse.
Second-line
Offer paƟents with psoriasis topical therapy.
Offer phototherapy or systemic therapy at the same Ɵme when topical therapy alone is unlikely to adequately control psoriasis, eg: > extensive disease (>10% BSA) > at least 'moderate' on physician's global assessment > where topical therapy is ineffecƟve (eg nail disease).
First-line
Offer biological therapy.
Consider changing to an alternaƟve biological drug in adults with psoriasis who:
• do not respond adequately to the first biological therapy (as defined in NICE TAG; primary failure) • lose iniƟal adequate response (secondary failure) • cannot tolerate or develop a contraindicaƟon to the iniƟal biological drug.
Third-line
If there is an inadequate response to the second biologic drug, seek supra-specialist advice. -what aspects of the person's daily living are affected by their psoriasis -how they are coping with their skin condition and any treatments they are using -if they need further advice or support -if their psoriasis has an impact on their mood -if their psoriasis causes them distress (be aware that they may have levels of distress but not be clinically depressed) -if their condition has any impact on their family or carers > Ask children and young people age-appropriate questions
Consensus

Referral of people with psoriasis for specialist care
4 > Following assessment in a non-dermatology setting, refer people for dermatology specialist advice if:
-there is diagnostic uncertainty, or -any type of psoriasis is severe or extensive -for example, more than 10% of the body surface area is affected, or -any type of psoriasis cannot be controlled with topical therapy, or -acute guttate psoriasis requires phototherapy, or -nail disease has a major functional or cosmetic impact, or -any type of psoriasis is having a major impact on a person's physical, psychological or social well-being 
Limitations of the guideline
Although the recommendations in the NICE guideline 9 are based on the best available evidence, consensus recommendations were required in a number of key areas due to a lack of available evidence, particularly surrounding assessment tools in primary care and all aspects of paediatric care for psoriasis.
Recommendations can be based only on the best assessment methods currently available, although these are not without fault. For example, estimating body surface area (BSA) involvement can be diffi cult, especially with small plaque or guttate psoriasis, and there were gaps in the evidence. However, the benefi ts of considering the extent of disease and the clinical utility of this tool for all types of psoriasis in all settings outweigh this limitation.
When considering the optimum approach to assessment and referral for psoriatic arthritis, the guideline development group weighed up the healthcare setting, the time taken to complete assessments and the degree of expertise required to use and interpret the scores. The psoriasis epidemiology screening tool (PEST) questionnaire 11 was considered to offer the best overall balance, being simple and easy to administer and having good sensitivity. However, uncertainty remains about the most appropriate tool due to the paucity of data.
In all of these areas, therefore, further research is required, and the guideline may need to be updated accordingly. The guideline therefore elaborates on best practice based on the current evidence. Clinicians need to judge on a case-by-case basis the most appropriate timing and method to assess comorbidities in order to offer preventive advice while avoiding unnecessary anxiety in people with psoriasis.
Implications and implementation
The main barrier to successful implementation of this guidance is likely to be insuffi cient training or understanding about psoriasis among healthcare professionals, as dermatology training is not compulsory. Formal assessment of psoriasis may represent a substantial shift in approach, and the recently published quality standards 24 and implementation tools that will be developed will support its application in practice. ■ Moderate quality CG = clinical guideline; NICE = National Institute for Health and Care Excellence; PEST = psoriasis epidemiological screening tool; PH = public health guidance. Severe psoriasis was defined as either requiring treatment with phototherapy or systemic agents, or requiring hospital admission in the studies underpinning this recommendation.
